5-azacytidine

Recurrent Ovarian Carcinoma

M.D. Anderson Cancer CenterPhase 1Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

54 Active assets in the Recurrent Ovarian Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Tianjin Medical University Cancer Institute and Hospital	Phase 4	BBB
(+)-VINCRISTINE Yonsei University	Phase 4	BBB
Olaparib Imunon	Phase 4	BB
Palbociclib University Medical Center Groningen	Phase 4	BB
Vinorelbine OHSU Knight Cancer Institute	Phase 2	BB

View all 50 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant

BB

Indicative ·

70 / 100

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant

BB

Indicative ·

65 / 100

myelodysplastic syndromeDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.